Buck Stops With Kraemer: Baxter CEO Resigns To Restore Investor Confidence
This article was originally published in The Gray Sheet
Executive Summary
A fresh round of restructuring will save Baxter $200 mil.-$300 mil. a year, shore up core business segments and help pave the way for future growth, the firm says
You may also be interested in...
People In Brief
Ex-Baxter CEO: Harry Kraemer, who resigned from Baxter in early 2004 following a string of earnings disappointments, joins private equity firm Madison Dearborn Partners as an executive partner April 27 (1"The Gray Sheet" Feb. 2, 2004, p. 11). Currently an adjunct professor at Northwestern University's Kellogg School of Management, Kraemer plans to continue teaching two days a week. Madison Dearborn invests in a wide range of healthcare companies, including kidney dialysis center chain Dialysis Centers of America and ancillary services provider Path Lab Holdings...
People In Brief
Ex-Baxter CEO: Harry Kraemer, who resigned from Baxter in early 2004 following a string of earnings disappointments, joins private equity firm Madison Dearborn Partners as an executive partner April 27 (1"The Gray Sheet" Feb. 2, 2004, p. 11). Currently an adjunct professor at Northwestern University's Kellogg School of Management, Kraemer plans to continue teaching two days a week. Madison Dearborn invests in a wide range of healthcare companies, including kidney dialysis center chain Dialysis Centers of America and ancillary services provider Path Lab Holdings...
“Realistic” CEO Parkinson Will Lead Baxter Through Continued Restructuring
Baxter's decision to tap former Abbott exec Robert Parkinson as chairman and CEO sets the stage for swift operational reforms at the highly diversified firm